Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature

Anti-programmed death 1 (PD-1) immune checkpoint inhibitors have produced robust tumor responses in several solid tumors including lung cancer by enhancing the antitumor activity of the immune system. In general, the adverse events triggered by anti-PD-1/PD-L1 mAbs appear to be less severe when comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Zhiyao, Sun, Xianwen, Chen, Wei, Tang, Wei, Gao, Beili, Xiang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422098/
https://www.ncbi.nlm.nih.gov/pubmed/34532495
http://dx.doi.org/10.21037/atm-21-4167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422098/
https://www.ncbi.nlm.nih.gov/pubmed/34532495
http://dx.doi.org/10.21037/atm-21-4167

Ejemplares similares